Cite
MLA Citation
John J. Kim et al.. “Lenvatinib Versus Sorafenib as First‐Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis.” Oncologist, vol. 25, 2020, pp. e512–e519. http://access.bl.uk/ark:/81055/vdc_100103685695.0x000036